Replies to post #250616 on Biotech Values

[RVNCfan]

Right I agree.
Bioage's MoA, APJ agonist looks very promising but IMHO the data for it is still not enough to invest.
If you see veru's data, they showed 5% fat loss and muscle gain if their subjects were obesity the fat loss could be way greater than 5% with Enobosarm alone.